Literature DB >> 11929082

Lymphocyte subset pattern in acromegaly.

A Colao1, D Ferone, P Marzullo, N Panza, R Pivonello, F Orio, G Grande, N Bevilacqua, G Lombardi.   

Abstract

Immune function in acromegalic patients has been poorly investigated. The aim of this study was to evaluate the main surface antigen clusters of circulating lymphocytes in acromegaly. One hundred patients with active acromegaly (55 women and 45 men, aged 20-70 yr) and 200 healthy subjects sex- and age-matched with the patients (110 women and 90 men, aged 20-70 yr) were enrolled in this study. All patients and controls were born and live in Southern Italy. No patient had received octreotide, bromocriptine or corticosteroids for at least 3 months before entering the study. The analysis of lymphocyte subset pattern was performed by flow cytometry and fluorescein isothiocyanate or phycoerythrin directly conjugated monoclonal antibodies specific for the cell surface antigen clusters (CD) representing T-cell population as a whole (CD3), T helpers (CD4), T suppressors (CD8), natural killer cells (CD16) and B-cell population as a whole (CD19). Acromegalics had significantly increased levels of CD3 (67.1+/-7.2 vs 64.3+/-8.8%; p=0.03) and CD4 (37.8+/-3.5 vs 36.4+/-4.3%; p=0.004) and decreased levels of CD8 (31.4+/-3.3 vs 33.7+/-8.2%; p<0.01) and CD19 (12.1+/-3.1 vs 15.2+/-5.1; p=0.01) without age-difference. The results of the current study demonstrate an increase in T-cell activity together with a decrease in B-cell activity in a very large series of patients with active acromegaly. These data further support the existence of abnormalities of the immune system in patients with chronic GH/IGF-1 excess.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11929082     DOI: 10.1007/BF03343975

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  36 in total

Review 1.  Growth hormone, lymphocytes and macrophages.

Authors:  K W Kelley
Journal:  Biochem Pharmacol       Date:  1989-03-01       Impact factor: 5.858

Review 2.  Clinical review 18: Are patients with acromegaly at increased risk for neoplasia?

Authors:  S Ezzat; S Melmed
Journal:  J Clin Endocrinol Metab       Date:  1991-02       Impact factor: 5.958

3.  Insulin-like growth factor I and the development of colorectal neoplasia in acromegaly.

Authors:  P J Jenkins; V Frajese; A M Jones; C Camacho-Hubner; D G Lowe; P D Fairclough; S L Chew; A B Grossman; J P Monson; G M Besser
Journal:  J Clin Endocrinol Metab       Date:  2000-09       Impact factor: 5.958

Review 4.  Growth-hormone and prolactin excess.

Authors:  A Colao; G Lombardi
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

5.  Changes in natural killer cells, the CD57CD8 subset, and related cytokines in healthy aging.

Authors:  S E McNerlan; I M Rea; H D Alexander; T C Morris
Journal:  J Clin Immunol       Date:  1998-01       Impact factor: 8.317

6.  Cytological changes in the mouse anterior pituitary after neonatal thymectomy: a light ane electron microscopical study.

Authors:  E Biachi; W Pierpaoli; E Sorkin
Journal:  J Endocrinol       Date:  1971-09       Impact factor: 4.286

7.  Benign and malignant tumors in patients with acromegaly.

Authors:  J Barzilay; G J Heatley; G W Cushing
Journal:  Arch Intern Med       Date:  1991-08

8.  Immune function in transgenic mice overexpressing growth hormone (GH) releasing hormone, GH or GH antagonist.

Authors:  E Dialynas; H Brown-Borg; A Bartke
Journal:  Proc Soc Exp Biol Med       Date:  1999-07

9.  Determinants of clinical outcome and survival in acromegaly.

Authors:  C Rajasoorya; I M Holdaway; P Wrightson; D J Scott; H K Ibbertson
Journal:  Clin Endocrinol (Oxf)       Date:  1994-07       Impact factor: 3.478

10.  Possible effects of growth hormone on development of acute lymphoblastic leukaemia.

Authors:  P C Rogers; D Komp; A Rogol; H Sabio
Journal:  Lancet       Date:  1977-08-27       Impact factor: 79.321

View more
  7 in total

Review 1.  Improving immunity in the elderly: current and future lessons from nonhuman primate models.

Authors:  Christine Meyer; Amelia Kerns; Kristen Haberthur; Ilhem Messaoudi
Journal:  Age (Dordr)       Date:  2011-12-20

2.  Hypersomatotropism induced secondary polycythaemia leading to spontaneous pituitary apoplexy resulting in cure of acromegaly and remission of polycythaemia: 'The virtuous circle'.

Authors:  Shinjan Patra; Sugata Narayan Biswas; Joydip Datta; Partha Pratim Chakraborty
Journal:  BMJ Case Rep       Date:  2017-12-07

Review 3.  Polycythemia as rare secondary direct manifestation of acromegaly: management and single-centre epidemiological data.

Authors:  Gabriele Zoppoli; Federico Bianchi; Andrea Bruzzone; Alessandro Calvia; Caterina Oneto; Caterina Passalia; Enrico Balleari; Davide Bedognetti; Elena Ponomareva; Elena Nazzari; Lara Castelletti; Lucio Castellan; Francesco Minuto; Riccardo Ghio; Diego Ferone
Journal:  Pituitary       Date:  2012-06       Impact factor: 4.107

4.  Failure of antibody response to polysaccharide antigen in treated panhypopituitary adults.

Authors:  A Mukherjee; M Helbert; W D J Ryder; R Borrow; J R E Davis; S M Shalet
Journal:  Clin Exp Immunol       Date:  2009-02-10       Impact factor: 4.330

5.  Sudden death due to aortic rupture in acromegaly.

Authors:  Pietro Maffei; Carla Menegazzo; Mauro Michelotto; Roberto Salmaso; Chiara Martini; Eugenio De Carlo; Marta Carli; Martina Barban; Ambrogio Fassina; Roberto Vettor; Nicola Sicolo
Journal:  Heart Vessels       Date:  2008-02-14       Impact factor: 2.037

Review 6.  Function of matrix IGF-1 in coupling bone resorption and formation.

Authors:  Janet L Crane; Xu Cao
Journal:  J Mol Med (Berl)       Date:  2013-09-26       Impact factor: 4.599

7.  Reductions in serum IGF-1 during aging impair health span.

Authors:  Zhenwei Gong; Oran Kennedy; Hui Sun; YingJie Wu; Garry A Williams; Laura Klein; Luis Cardoso; Ronald W Matheny; Gene B Hubbard; Yuji Ikeno; Roger P Farrar; Mitchell B Schaffler; Martin L Adamo; Radhika H Muzumdar; Shoshana Yakar
Journal:  Aging Cell       Date:  2013-12-30       Impact factor: 9.304

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.